Treating ovarian cancer with the drug bevacizumab ("Avastin") delays the disease and may also improve survival, show the results of an international clinical trial co-led by Drs. Amit Oza of the Princess Margaret Cancer Program, University Health Network and Timothy Perren, St James's Institute of Oncology, Leeds, UK.

Half the drugs used today target a single class of proteins - and now scientists have identified an important molecular player critical to the proper workings of those proteins critical to our health.

How sildenafil, the active ingredient in Viagra, can alleviate heart problems is reported by Bochum's researchers in cooperation with colleagues from the Mayo Clinic in Rochester (Minnesota) in the journal Circulation.

Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.

The research team at Lyon has developed an animal model carrying a mutation of the DCC gene. Mice carrying the mutation develop tumours, because this gene can no longer induce the death of the cancer cells. This discovery could lead to the development of a new targeted cancer treatment that aims to reactivate the dying of cancer cells.

Scientists are about to make publicly available all the data they have so far on the genetic blueprint of medicinal plants and what beneficial properties are encoded by the genes identified.

Loyola University Medical Center researchers are reporting what could become the first reliable method to predict whether an antidepressant will work on a depressed patient. The method would involve a blood test for a protein called vascular endothelial growth factor (VEGF).